We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Markers May Predict Prostate Cancer in Younger Men

By LabMedica International staff writers
Posted on 12 Jul 2010
Prostate cancer has become more common in younger men, and it is frequently more aggressive. More...
A new study has found that a series of genetic mutations could help detect this early onset prostate cancer.

Researchers believe that genetics and traditional screening techniques could play a role in predicting the risk of prostate cancer in younger men. "This is a potential opportunity to combine PSA [prostate-specific antigen] testing with genetic markers to determine who has significant prostate cancer. It could be a combination of age and family history that could help us determine who should be tested with PSA and a panel of genetic markers,” stated study author Kathleen Cooney, M.D., professor of hematology/oncology and division chief of hematology/oncology at the University of Michigan (U-M) Medical School (Ann Arbor, MI, USA).

Researchers looked for 14 different gene mutations in 754 men age 56 and younger with prostate cancer. The men were enrolled in the Prostate Cancer Genetics Project at U-M. Researchers also looked at 1,163 older men with prostate cancer and 2,713 men without prostate cancer. The study, which was presented June 2010 at the American Society of Clinical Oncology annual meeting, held in Chicago, IL, USA, discovered that the younger men carried more of these genetic mutations. Moreover, 30% of the younger men had aggressive prostate cancer and 41% of these men had at least one first-degree relative with prostate cancer.

"Early onset prostate cancer has a strong genetic component, which we saw in this study. The genetic variants we looked at here are likely not the best indicators. Our next step is to look more widely for common genetic variants among this group of men,” Dr. Cooney stated.

The researchers continue to enroll men in this study. They will next examine the genome of a larger population of men with early onset prostate cancer to find common mutations that may be linked to the disease.

Related Links:

University of Michigan (U-M) Medical School




Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.